AstraZeneca Pharma receives CDSCO nod for cancer treatment drug

AstraZeneca Pharma, in an exchange filing, said it has received the CDSCO’s permission to import for sales and distribution of the solution for infusion 120 mg ml and 500mg/10 ml for an additional indication.








